title: Beta-catenin expression is prognostic of improved non-small cell lung cancer survival.
abstract: BACKGROUND
  The objectives of this study were to determine the frequency and prognostic significance of beta-catenin expression in a cohort of non-small cell lung cancer (NSCLC) patients.
  
  
  METHODS
  Tissue microarrays were constructed using clinically annotated formalin-fixed paraffin-embedded tumor samples from individuals diagnosed with NSCLC who underwent surgical resection with curative intent and had beta-catenin expression status determined by immunohistochemistry.
  
  
  RESULTS
  Negative beta-catenin expression was seen in 28% (103/370) of NSCLC cases and was prognostic of a reduced overall patient survival (P = .008) and also was significantly correlated with the presence of lymphatic invasion (P = .015). In multivariate analysis, the loss of beta-catenin expression retained independent prognostic significance and showed an adjusted hazard ratio of 3.18 (confidence interval, 1.46-6.91, P = .004) for reduced patient survival when adjusting for the presence of lymphatic invasion, tumor grade, nodal status, and tumor stage.
  
  
  CONCLUSIONS
  Beta-catenin represents an important prognostic marker in individuals diagnosed with surgically resectable NSCLC.
authors.affiliation: Department of Surgery, St. Paul's Hospital, University of British Columbia, C303-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6.
authors.forename: Connie G
authors.initials: CG
authors.lastname: Chiu
authors.affiliation: Department of Medical Genetics, University of British Columbia and Michael Smith Genome Sciences Center, British Columbia Cancer Research Center, Vancouver, BC, Canada.
authors.forename: Simon K
authors.initials: SK
authors.lastname: Chan
authors.affiliation: Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Z Amy
authors.initials: ZA
authors.lastname: Fang
authors.affiliation: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Hamid
authors.initials: H
authors.lastname: Masoudi
authors.affiliation: Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada; Menzies Research Institute, Tasmania, Hobart, Tasmania, Australia.
authors.forename: Richard
authors.initials: R
authors.lastname: Wood-Baker
authors.affiliation: Department of Medical Genetics, University of British Columbia and Michael Smith Genome Sciences Center, British Columbia Cancer Research Center, Vancouver, BC, Canada.
authors.forename: Steven J M
authors.initials: SJM
authors.lastname: Jones
authors.affiliation: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada.
authors.forename: Blake
authors.initials: B
authors.lastname: Gilks
authors.affiliation: Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
authors.forename: Janessa
authors.initials: J
authors.lastname: Laskin
authors.affiliation: Department of Surgery, St. Paul's Hospital, University of British Columbia, C303-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. Electronic address: smwiseman@providencehealth.bc.ca.
authors.forename: Sam M
authors.initials: SM
authors.lastname: Wiseman
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D051176:beta Catenin / Q000096:biosynthesis*
chemical_list: D051176:beta Catenin